drugset / Trial / NCT02143635
Study to Determine and Evaluate a Safe and Tolerated Dose of HDM201 in Patients With Selected Advanced Tumors That Are TP53wt
Non-randomizedParallel-groupOpen-labelTreatment
Summary
To determine and evaluate a safe and tolerated dose of HDM201 in adult patients with selected advanced tumors characterized by wild-type TP53.
Timeline
- Start
- 2014-07-07
- Primary completion
- 2017-06-20
- Completion
- 2020-06-09
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Siremadlin | Small molecule | — | — |
Indications
No indication recorded.